


IN THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claim 1. (original) A compound of structural formula I:



(I)

or a pharmaceutically acceptable salt thereof, wherein;

R¹ is selected from:

- (1) aryl,
- (2) aryl-C₁₋₄alkyl,
- (3) heteroaryl,
- (4) heteroaryl-C₁₋₄alkyl,

wherein each alkyl is optionally substituted with one to four substituents independently selected from R^a, and each aryl and heteroaryl are optionally substituted with one to four substituents independently selected from R^b;

R² is selected from:

- (1) C₁₋₁₀alkyl,
- (2) C₃₋₁₀cycloalkyl-C₁₋₄alkyl,
- (3) cycloheteroalkyl,
- (4) cycloheteroalkyl-C₁₋₄alkyl,
- (5) aryl,
- (6) aryl-C₁₋₄alkyl,
- (7) heteroaryl, and
- (8) heteroaryl-C₁₋₄alkyl,

wherein each alkyl is optionally substituted with one to four substituents independently selected from R^a, and each cycloalkyl, cycloheteroalkyl, aryl and heteroaryl is optionally substituted with one to four substituents independently selected from R^b;

R³ is selected from:

- (1) hydrogen, and
- (2) C₁₋₄alkyl,

wherein each alkyl is optionally substituted with one to four substituents independently selected from R^a;

R⁴ is selected from:

- (1) hydrogen, and
- (2) C₁₋₄alkyl,

wherein each alkyl is optionally substituted with one to four substituents independently selected from R^a;

R⁵ is selected from:

- (1) C₁₋₁₀alkyl,
- (2) C₂₋₁₀alkenyl,
- (3) C₃₋₁₀cycloalkyl,
- (4) C₃₋₁₀cycloalkyl-C₁₋₁₀alkyl,
- (5) cycloheteroalkyl-C₁₋₁₀alkyl,
- (6) aryl-C₁₋₁₀alkyl,
- (7) diaryl-C₁₋₁₀alkyl,
- (8) aryl-C₂₋₁₀alkenyl,
- (9) heteroaryl-C₁₋₁₀alkyl,
- (10) -OR^d,
- (11) -S(O)_mR^d, and
- (12) -NR^cR^d,

wherein alkyl, alkenyl, cycloalkyl, and cycloheteroalkyl are optionally substituted with one to four substituents independently selected from R^a and cycloalkyl, cycloheteroalkyl, aryl and heteroaryl are optionally substituted with one to four substituents independently selected from R^b, provided that R⁵ is not -CH=CH-COOH;

R⁶ is selected from:

- (1) C₁₋₄alkyl,
- (2) C₂₋₄alkenyl,
- (3) C₂₋₄alkynyl,
- (4) -OR^d,
- (5) halogen,
- (6) -CN, and
- (7) -NR^cR^d,

wherein alkyl, alkenyl, and alkynyl are optionally substituted with one to four substituents independently selected from R^a;

each R^a is independently selected from:

- (1) -OR^d,
- (2) -NR^cS(O)_mR^d,
- (3) halogen,

- (4) $-\text{S}(\text{O})_m\text{R}^d$,
- (5) $-\text{S}(\text{O})_m\text{NR}^c\text{R}^d$,
- (6) $-\text{NR}^c\text{R}^d$,
- (7) $-\text{C}(\text{O})\text{R}^d$,
- (8) $-\text{CO}_2\text{R}^d$,
- (9) $-\text{CN}$,
- (10) $-\text{C}(\text{O})\text{NR}^c\text{R}^d$,
- (11) $-\text{NR}^c\text{C}(\text{O})\text{R}^d$,
- (12) $-\text{NR}^c\text{C}(\text{O})\text{OR}^d$,
- (13) $-\text{NR}^c\text{C}(\text{O})\text{NR}^c\text{R}^d$,
- (14) $-\text{CF}_3$,
- (15) $-\text{OCF}_3$, and
- (16) cycloheteroalkyl;

each R^b is independently selected from:

- (1) R^a ,
- (2) $\text{C}_{1-10}\text{alkyl}$,
- (3) oxo,
- (4) aryl,
- (5) $\text{arylC}_{1-4}\text{alkyl}$,
- (6) heteroaryl, and
- (7) heteroaryl $\text{C}_{1-4}\text{alkyl}$;

R^c and R^d are independently selected from:

- (1) hydrogen,
- (2) $\text{C}_{1-10}\text{alkyl}$,
- (3) $\text{C}_{2-10}\text{alkenyl}$,
- (4) cycloalkyl,
- (5) cycloalkyl- $\text{C}_{1-10}\text{alkyl}$;
- (6) cycloheteroalkyl,
- (7) cycloheteroalkyl- $\text{C}_{1-10}\text{alkyl}$;
- (8) aryl,
- (9) heteroaryl,
- (10) aryl- $\text{C}_{1-10}\text{alkyl}$, and
- (11) heteroaryl- $\text{C}_{1-10}\text{alkyl}$, or

R^c and R^d together with the atom(s) to which they are attached form a heterocyclic ring of 4 to 7 members containing 0-2 additional heteroatoms independently selected from oxygen, sulfur and N-
 R_g ,

each R^c and R^d may be unsubstituted or substituted with one to three substituents selected from R^h ;
each R^g is independently selected from: C_{1-10} alkyl, and $-C(O)R^c$;

each R^h is independently selected from:

- (1) halogen,
- (2) C_{1-10} alkyl,
- (3) $-O C_{1-4}$ alkyl,
- (4) $-S(O)_m C_{1-4}$ alkyl,
- (5) $-CN$,
- (6) $-CF_3$, and
- (7) $-OCF_3$; and

m is selected from 0, 1 and 2.

Claim 2. (original) The compound according to Claim 1, wherein R^4 is selected from:

- (1) hydrogen, and
- (2) methyl;

and pharmaceutically acceptable salts thereof.

Claim 3. (original) The compound according to Claim 2, wherein R^4 is hydrogen;
and pharmaceutically acceptable salts thereof.

Claim 4. (original) The compound according to Claim 2, wherein R^3 is selected from
hydrogen, methyl and ethyl; and pharmaceutically acceptable salts thereof.

Claim 5. (original) The compound according to Claim 3, wherein R^3 is methyl; and
pharmaceutically acceptable salts thereof.

Claim 6. (original) The compound according to Claim 4, wherein R^1 is selected from:

- (1) phenyl,
- (2) phenyl- C_{1-4} alkyl,
- (3) pyridyl, and
- (4) pyridyl- C_{1-4} alkyl,

wherein each phenyl and pyridyl is optionally substituted with one or two substituents selected from
halogen, methyl, trifluoromethyl, cyano and methoxy, and each pyridyl is optionally present as the N-
oxide;

and pharmaceutically acceptable salts thereof.

Claim 7. (original) The compound according to Claim 5, wherein R¹ is phenyl, unsubstituted or substituted with a halogen or cyano substituent; and pharmaceutically acceptable salts thereof.

Claim 8. (currently amended) The compound according to Claim 6, wherein R² is selected from:

- (1) isopropyl,
- (2) isobutyl,
- (3) n-propyl,
- (4) n-butyl,
- (5) cyclopropylmethyl,
- (6) cyclobutylmethyl,
- (7) cyclopentylmethyl,
- (8) cyclohexylmethyl,
- (9) phenyl,
- (10) benzyl,
- (11) phenylethyl,
- (12) 3-phenylpropyl,
- (13) 2-phenylpropyl, and
- (14) pyridylmethyl,

wherein each cycloalkyl, aryl and heteroaryl is optionally substituted with one or two R^b substituents selected from halogen, trifluoromethyl, cyano, methoxycarbonyl, and methoxy; and pharmaceutically acceptable salts thereof.

Claim 9. (original) The compound according to Claim 7, wherein R² is 4-chlorobenzyl, and pharmaceutically acceptable salts thereof.

Claim 10. (original) The compound according to Claim 9, wherein R⁶ is selected from:

- (1) methyl,
- (2) hydroxyl,
- (3) halogen, and
- (4) -CN;

and pharmaceutically acceptable salts thereof.

Claim 11. (original) The compound according to Claim 9, wherein R⁵ is selected from:

- (1) C₁-8alkyl,

- (2) C₂-galkenyl,
- (3) cycloheteroalkyl-C₁-galkyl,
- (4) aryl-C₁-galkyl,
- (5) diaryl-C₁-4alkyl,
- (6) aryl-C₂-galkenyl,
- (7) heteroaryl-C₁-galkyl,
- (8) -OR^d, and
- (9) -NR^cR^d,


wherein each alkyl or alkenyl is optionally substituted with one or two substituents independently selected from R^a, and each cycloalkyl, cycloheteroalkyl, aryl and heteroaryl is each optionally substituted with one to three substituents independently selected from R^b and wherein cycloheteroalkyl is selected from pyrrolidinyl, 2H-phthalazinyl, azabicyclo[2.2.1]heptanyl, benzoxapinyl, morpholinyl, piperazinyl, dihydroimidazo[2,1-b]thiazolyl, and piperidinyl; aryl is selected from phenyl and naphthyl; and heteroaryl is selected from pyridyl, pyrimidinyl, pyridazinyl, pyrazolyl, triazolyl, benzothiazolyl, benzoxazolyl, isoxazolyl, indolyl and thiazolyl; and pharmaceutically acceptable salts thereof.

Claim 12. (original) The compound according to Claim 10, wherein R⁵ is selected from:

- (1) C₁-galkyl substituted with -OR^d or NR^cR^d,
- (2) C₂-8 alkenyl substituted with OR^d or NR^cR^d, and
- (3) phenyl-C₁-8 alkyl wherein phenyl is substituted with one to three R^b substituents;

and pharmaceutically acceptable salts thereof.

Claim 13. (original) The compound according to Claim 12, wherein R⁵ is:



and pharmaceutically acceptable salts thereof.

Claim 14. (currently amended) The compound according to Claim 1, selected from:

N-{[3-(4-chlorophenyl)-2-(3-bromophenyl)-1,2-dimethyl]propyl}-2-(5-trifluoromethyl-2-pyridyloxy)-2-methylpropanamide,
N-{[3-(4-chlorophenyl)-2-cyano-2-phenyl-1-methyl]propyl}-2-(5-trifluoromethyl-2-pyridyloxy)-2-methylpropanamide,
N-{[3-(4-chlorophenyl)-2-(3-bromophenyl)-2-hydroxy]propyl}-2-(5-trifluoromethyl-2-pyridyloxy)-2-methylpropanamide,

N-{[3-(4-chlorophenyl)-2-(3-bromophenyl)-2-fluoro-1(S)-methyl]propyl}-2-(5-trifluoromethyl-2-pyridyloxy)-2-methylpropanamide,
N-{[3-(4-chlorophenyl)-2-(3-cyanophenyl)-2-fluoro-1(S)-methyl]propyl}-2-(5-trifluoromethyl-2-pyridyloxy)-2-methylpropanamide,
N-{[3-(4-chlorophenyl)-2-(3-cyanophenyl)-2-fluoro-1(S)-methyl]propyl}-2-(5-trifluoromethyl-2-pyridyloxy)-2-methylpropanamide,
N-{[3-(4-chlorophenyl)-2-(3-bromophenyl)-2-hydroxy-1(S)-methyl]propyl}-2-(5-trifluoromethyl-2-pyridyloxy)-2-methylpropanamide, *N*-{[3-(4-chlorophenyl)-2-(3-bromophenyl)-2-hydroxy-1(R)-methyl]propyl}-2-(5-trifluoromethyl-2-pyridyloxy)-2-methylpropanamide, 1-{[3-(4-chlorophenyl)-2-(3-cyanophenyl)-2-fluoro-1(S)-methyl]propyl}-3-[2-(phenyl)ethyl]urea,
1-{[3-(4-chlorophenyl)-2-(3-cyanophenyl)-2-hydroxy-1(S)-methyl]propyl}-3-[2-(4-chlorophenyl)ethyl]urea,
1-{[3-(4-chlorophenyl)-2-(3-cyanophenyl)-2-hydroxy-1(S)-methyl]propyl}-3-methyl-3-[2-(phenyl)ethyl]urea,
1-{[3-(4-chlorophenyl)-2-(3-cyanophenyl)-2-hydroxy-1(S)-methyl]propyl}-3-[1-(4-chlorophenyl)ethyl]urea,
N-{[3-(4-chlorophenyl)-2-(3-cyanophenyl)-2-hydroxy-1(S)-methyl]propyl}-2-phenylbutanamide,
N-{[3-(4-chlorophenyl)-2-(3-cyanophenyl)-2-fluoro-1(S)-methyl]propyl}-1-ethylcyclobutanecarboxamide,
N-{[3-(4-chlorophenyl)-2-(3-cyanophenyl)-2-hydroxy-1(S)-methyl]propyl}-1-phenylcyclobutanecarboxamide,
N-{[3-(4-chlorophenyl)-2-(3-cyanophenyl)-2-hydroxy-1(S)-methyl]propyl}-2-phenylbutanamide,
and pharmaceutically acceptable salts thereof.

Claim 15. (original) A method of treating a disease mediated by the Cannabinoid-1 receptor comprising administration to a patient in need of such treatment of a therapeutically effective amount of a compound according to Claim 1.

Claim 16. (original) The method according to Claim 15 wherein the disease mediated by the Cannabinoid-1 receptor is selected from: psychosis, memory deficit, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders, cerebral vascular accidents, head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, schizophrenia, substance abuse disorders, constipation, chronic intestinal pseudo-obstruction, cirrhosis of the liver, asthma, obesity, and other eating disorders associated with excessive food intake.

Claim 17. (original) The method according to Claim 16 wherein the disease mediated by the Cannabinoid-1 receptor is an eating disorder associated with excessive food intake.

Claim 18. (currently amended) The method according to Claim 17 wherein the eating disorder ~~asssociated~~ associated with excessive food intake is selected from obesity, bulimia nervosa, and compulsive eating disorders.

Claim 19. (original) The method according to Claim 18 wherein the eating disorder associated with excessive food intake is obesity.

Claim 20. (original) A method of preventing obesity in a person at risk for obesity comprising administration to said person of about 0.001 mg to about 100 mg per kg of a compound according to Claim 1.

Claim 21. (original) A composition comprising a compound according to Claim 1 and a pharmaceutically acceptable carrier.

Claims 22-27. (canceled)

Claim 28. (new) The compound according to Claim 9, wherein:
R⁶ is selected from:

- (1) methyl,
- (2) halogen, and
- (3) -CN;

and pharmaceutically acceptable salts thereof.

Claim 29. (new) The compound according to Claim 28, selected from the group consisting of:

N-{[3-(4-chlorophenyl)-2-(3-bromophenyl)-1,2-dimethyl]propyl}-2-(5-trifluoromethyl-2-pyridyloxy)-2-methylpropanamide,
N-{[3-(4-chlorophenyl)-2-cyano-2-phenyl-1-methyl]propyl}-2-(5-trifluoromethyl-2-pyridyloxy)-2-methylpropanamide,
N-{[3-(4-chlorophenyl)-2-(3-bromophenyl)-2-fluoro-1(S)-methyl]propyl}-2-(5-trifluoromethyl-2-pyridyloxy)-2-methylpropanamide,
N-{[3-(4-chlorophenyl)-2-(3-cyanophenyl)-2-fluoro-1(S)-methyl]propyl}-2-(5-trifluoromethyl-2-pyridyloxy)-2-methylpropanamide,

N-{[3-(4-chlorophenyl)-2-(3-cyanophenyl)-1,2-dimethyl]propyl}-2-(5-trifluoromethyl-2-pyridyloxy)-2-methylpropanamide,
1-{[3-(4-chlorophenyl)-2-(3-cyanophenyl)-2-fluoro-1(S)-methyl]propyl}-3-[2-(phenyl)ethyl]urea,
N-{[3-(4-chlorophenyl)-2-(3-cyanophenyl)-2-fluoro-1(S)-methyl]propyl}-1-ethyl-cyclobutanecarboxamide,
and pharmaceutically acceptable salts thereof.

Claim 30. (new) The compound according to Claim 9, wherein R⁶ is hydroxy, and pharmaceutically acceptable salts thereof.

Claim 31. (new) The compound according to Claim 30, selected from the group consisting of:
N-{[3-(4-chlorophenyl)-2-(3-bromophenyl)-2-hydroxy]propyl}-2-(5-trifluoromethyl-2-pyridyloxy)-2-methylpropanamide,
N-{[3-(4-chlorophenyl)-2-(3-bromophenyl)-2-hydroxy-1(S)-methyl]propyl}-2-(5-trifluoromethyl-2-pyridyloxy)-2-methylpropanamide, *N*-{[3-(4-chlorophenyl)-2-(3-bromophenyl)-2-hydroxy-1(R)-methyl]propyl}-2-(5-trifluoromethyl-2-pyridyloxy)-2-methylpropanamide, 1-{[3-(4-chlorophenyl)-2-(3-cyanophenyl)-2-hydroxy-1(S)-methyl]propyl}-3-[2-(4-chlorophenyl)ethyl]urea,
1-{[3-(4-chlorophenyl)-2-(3-cyanophenyl)-2-hydroxy-1(S)-methyl]propyl}-3-methyl-3-[2-(phenyl)ethyl]urea,
1-{[3-(4-chlorophenyl)-2-(3-cyanophenyl)-2-hydroxy-1(S)-methyl]propyl}-3-[1-(4-chlorophenyl)ethyl]urea,
N-{[3-(4-chlorophenyl)-2-(3-cyanophenyl)-2-hydroxy-1(S)-methyl]propyl}-2-phenylbutanamide,
N-{[3-(4-chlorophenyl)-2-(3-cyanophenyl)-2-hydroxy-1(S)-methyl]propyl}-1-phenyl-cyclobutanecarboxamide,
N-{[3-(4-chlorophenyl)-2-(3-cyanophenyl)-2-hydroxy-1(S)-methyl]propyl}-2-phenyl-butanamide,
and pharmaceutically acceptable salts thereof.

Claim 32. (new) A method of treating a disease mediated by the Cannabinoid-1 receptor comprising administration to a patient in need of such treatment of a composition according to Claim 21.


Claim 33. (new) The method according to Claim 32 wherein the disease mediated by the Cannabinoid-1 receptor is selected from: psychosis, memory deficit, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders, cerebral vascular accidents, head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, schizophrenia, substance abuse disorders, constipation, chronic intestinal pseudo-obstruction, cirrhosis of the liver, asthma, obesity, and other eating disorders associated with excessive food intake.

Claim 34. (new) The method according to Claim 33 wherein the disease mediated by the Cannabinoid-1 receptor is an eating disorder associated with excessive food intake.

Claim 35. (new) The method according to Claim 34 wherein the eating disorder associated with excessive food intake is selected from obesity, bulimia nervosa, and compulsive eating disorders.

Claim 36. (new) The method according to Claim 35 wherein the eating disorder associated with excessive food intake is obesity.

Claim 37. (new) The compound according to Claim 1 which is:



and pharmaceutically acceptable salts thereof.

Claim 38. (new) A composition comprising the compound according to Claim 37 and a pharmaceutically acceptable carrier.